Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21467457 | 0.79 | CHRM2 (0.43) | CYP19A1CA1CA2CA4 | |
| SCHEMBL19055335 | 0.73 | ALDH1A1 (0.39) | CYP19A1CA1CA2CA4 | |
| SCHEMBL16378461 | 0.73 | ALDH1A1 (0.39) | CYP19A1CA1CA2CA4 | |
| SCHEMBL19055312 | 0.73 | ALDH1A1 (0.39) | CYP19A1CA1CA2CA4 | |
| SCHEMBL257683 | 0.73 | ALDH1A1 (0.39) | CYP19A1CA1CA2CA4 | |
| SCHEMBL10388648 | 0.71 | CYP19A1 (0.33) | CYP19A1CYP2D6CA1CA2CA4 | |
| SCHEMBL12165146 | 0.71 | ALDH1A1 (0.38) | CYP19A1CA1CA2CA4 | |
| SCHEMBL137091 | 0.71 | CYP19A1 (0.33) | CYP19A1CYP2D6CA1CA2CA4 | |
| SCHEMBL12165148 | 0.71 | ALDH1A1 (0.38) | CYP19A1CA1CA2CA4 | |
| SCHEMBL14952751 | 0.71 | CYP19A1 (0.34) | CYP19A1CYP2D6CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184281-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | CYP19A1 3519/4885CYP2D6 4452/4885CA1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.